A retrospective observational multicenter study to compare efficacy and safety of Vedolizumab and Infliximab treatment for Immune-Mediated Diarrhea and Colitis in Cancer patients
Latest Information Update: 04 Jul 2021
At a glance
- Drugs Infliximab (Primary) ; Vedolizumab (Primary)
- Indications Colitis; Diarrhoea
- Focus Adverse reactions; Therapeutic Use
- 04 Jul 2021 New trial record
- 23 May 2021 Results presented at the Digestive Disease Week 2021